Clinical outcome of isolated Serous tubal intraepithelial carcinomas (STIC)

International Journal of Gynecological Cancer

Volumn 23, Issue 9, 2013, Pages 1603-1611

  Wethington, Stephanie L ^a   Park, Kay J ^a   Soslow, Robert A ^a   Kauff, Noah D ^a,b   Brown, Carol L ^a,b   Dao, Fanny ^a   Otegbeye, Ebunoluwa ^a   Sonoda, Yukio ^a,b   Abu Rustum, Nadeem R ^a,b   Barakat, Richard R ^a,b   Levine, Douglas A ^a,b   Gardner, Ginger J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Ovarian carcinoma; Prophylactic salpingo oophorectomy; Serous tubal intraepithelial carcinoma

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CARBOPLATIN; PACLITAXEL; PROTEIN P53;

ABDOMINAL HYSTERECTOMY; ADENOFIBROMA; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CARCINOMA; FAMILY HISTORY; FEMALE; FIMBRIA; FOLLOW UP; GENE MUTATION; HIGH RISK PATIENT; HUMAN; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MEDICAL RECORD REVIEW; OMENTECTOMY; OUTCOME ASSESSMENT; OVARY CARCINOMA; PELVIS LYMPH NODE; PELVIS LYMPHADENECTOMY; PERITONEAL BIOPSY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; SECRETORY CELL; SEROUS TUBAL INTRAEPITHELIAL CARCINOMA;

ADULT; AGED; CARCINOMA IN SITU; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84888357113     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182a80ac8     Document Type: Article

References (29)

1. Bannatyne P, Russell P. Early adenocarcinoma of the fallopian tubes. A case for multifocal tumorigenesis. Diagn Gynecol Obstet. 1981; 3: 49-60.
2. Pauerstein CJ. Pathophysiology of the fallopian tube. Clin Obstet Gynecol. 1974; 17: 89-119.
3. Russell P. The pathological assessment of ovarian neoplasms. III: The malignant "epithelial" tumours. Pathology. 1979; 11: 493-532.
4. Woodruff JD, Julian CG. Multiple malignancy in the upper genital canal. Am J Obstet Gynecol. 1969; 103: 810-822.
5. Yeung HH, Bannatyne P, Russell P. Adenocarcinoma of the fallopian tubes: a clinicopathological study of eight cases. Pathology. 1983; 15: 279-286.
6. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010; 34: 433-443.
7. Kurman RJ, Vang R, Junge J, et al. Papillary tubal hyperplasia: the putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am J Surg Pathol. 2011; 35: 1605-1614.
8. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006; 100: 58-64.
9. Agoff SN, Mendelin JE, Grieco VS, et al. Unexpected gynecologic neoplasms in patients with proven or suspected BRCA-1 or -2 mutations: implications for gross examination, cytology, and clinical follow-up. Am J Surg Pathol. 2002; 26: 171-178.
10. Vang R, Visvanathan K, Gross A, et al. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol. 2012; 31: 243-253.
11. Agoff SN, Garcia RL, Goff B, et al. Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations. Am J Surg Pathol. 2004; 28: 1112-1114.
12. Carcangiu ML, Peissel B, Pasini B, et al. Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature. Am J Surg Pathol. 2006; 30: 1222-1230.
13. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008; 26: 4160-4165.
14. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007; 25: 3985-3990.
15. Rabban JT, Krasik E, Chen LM, et al. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingo-oophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol. 2009; 33: 1878-1885.
16. Lamb JD, Garcia RL, Goff BA, et al. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol. 2006; 194: 1702-1709.
17. Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002; 87: 52-56.
18. Powell CB, Swisher EM, Cass I, et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol. 2013; 129: 364-71.
19. Manchanda R, Abdelraheim A, Johnson M, et al. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG. 2011; 118: 814-824.
20. Manchanda R, Drapkin R, Jacobs I, et al. The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer. Gynecol Oncol. 2012; 124: 185-191.
21. Reitsma W, de Bock GH, Oosterwijk JC, et al. Support of the 'fallopian tube hypothesis' in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer. 2013; 49: 132-141.
22. Powell CB. Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy. Gynecol Oncol. 2006; 100: 1-2.
23. Powell CB, Chen LM, McLennan J, et al. Risk-reducing salpingo- oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer. 2011; 21: 846-851.
24. Paley PJ, Swisher EM, Garcia RL, et al. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol. 2001; 80: 176-180.
25. Rabban JT, Barnes M, Chen LM, et al. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma. Am J Surg Pathol. 2009; 33: 1125-1136.
26. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010; 304: 967-975.
27. Bacha OM, Gregoire J, Grondin K, et al. Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population. Int J Gynecol Cancer. 2012; 22: 974-978.
28. Finkelman BS, Rubinstein WS, Friedman S, et al. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol. 2012; 30: 1321-1328.
29. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002; 346: 1609-1615.